Cargando…

Economic burden of illness among patients with pulmonary arterial hypertension (PAH) associated with connective tissue disorders (CTD)

Pulmonary arterial hypertension (PAH) is commonly associated with connective tissue disorders (CTDs). This study provides a contemporary assessment of the economic burden of CTD + PAH and PAH in the United States. Eligible adult patients identified from Optum's deidentified Clinformatics® Data...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tsang, Yuen, Panjabi, Sumeet, Funtanilla, Vienica, Germack, Hayley D., Gauthier‐Loiselle, Marjolaine, Manceur, Ameur M., Liu, Stephanie, Cloutier, Martin, Lefebvre, Patrick
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10084239/ https://www.ncbi.nlm.nih.gov/pubmed/37051491 http://dx.doi.org/10.1002/pul2.12218

Ejemplares similares

Real-World Treatment Patterns Among Patients with Connective Tissue Disorder-Related Pulmonary Arterial Hypertension in the United States: A Retrospective Claims-Based Analysis
por: Sargent, Therese, et al.
Publicado: (2023)

The societal economic burden of autosomal dominant polycystic kidney disease in the United States
por: Cloutier, Martin, et al.
Publicado: (2020)

Content Analysis of 2012-2019 FDA Warning Letters and Notices of Violations using the Economic, Clinical, and Humanistic Outcomes (ECHO) Model
por: Mohite, Namosha, et al.
Publicado: (2021)

Hospitalization Among Pulmonary Arterial Hypertension Patients With and Without Connective Tissue Disease Comorbidities Prescribed Oral Selexipag
por: Tsang, Yuen, et al.
Publicado: (2023)

Impact of the COVID‐19 pandemic on care disruptions, outcomes, and costs in patients receiving pulmonary arterial hypertension‐specific therapy in the United States of America: An observational study
por: George, Marjorie Patricia, et al.
Publicado: (2023)

Development of predictive risk models for major adverse cardiovascular events among patients with type 2 diabetes mellitus using health insurance claims data
por: Young, James B., et al.
Publicado: (2018)

Connecting The Dots (CTD 2022)
Publicado: (2022)

Connecting The Dots (CTD 2023)
por: Annovi, Alberto, et al.
Publicado: (2023)

Health-Related and Economic Burden Among Family Caregivers of Patients with Acute Myeloid Leukemia or Hematological Malignancies
por: Yucel, Emre, et al.
Publicado: (2021)

Connecting The Dots 2020 (CTD 2020)
por: Lange, David
Publicado: (2020)

Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial
por: Coghlan, John Gerry, et al.
Publicado: (2017)

Predicting Risk of 1-Year Hospitalization Among Patients with Pulmonary Arterial Hypertension
por: Zhang, Chang, et al.
Publicado: (2023)

The direct and indirect health care costs associated with pulmonary arterial hypertension among commercially insured patients in the United States
por: Ogbomo, Adesuwa, et al.
Publicado: (2022)

The economic burden of pulmonary arterial hypertension (PAH) in the US on payers and patients
por: Sikirica, Mirko, et al.
Publicado: (2014)

PReS-FINAL-2267: Successful treatment of pulmonary arterial hypertension associated with connective tissue disease (PAH-CTD) with combination therapy of sildenafil and ambrisentan: a case report
por: Yamaguchi, KI, et al.
Publicado: (2013)

Reasons for Treatment Changes in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Chart Review Study
por: Schein, Jeff, et al.
Publicado: (2022)

Postsurgical treatment landscape and economic burden of locoregional and distant recurrence in patients with operable nonmetastatic melanoma
por: Tarhini, Ahmad, et al.
Publicado: (2018)

Economic burden of disease progression among multiple myeloma patients who have received transplant and at least one line of therapy in the US
por: Fonseca, Rafael, et al.
Publicado: (2021)

Clinical burden of invasive Escherichia coli disease among older adult patients treated in hospitals in the United States
por: Hernandez-Pastor, Luis, et al.
Publicado: (2023)

Connecting the Dots and Workshop on Intelligent Trackers (CTD/WIT 2019)
por: Annovi, A, et al.
Publicado: (2019)

Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: post hoc analysis
por: Kuwana, Masataka, et al.
Publicado: (2020)

Real-World Analysis of Treatment Patterns Among Hospitalized Patients with Pulmonary Arterial Hypertension
por: Ogbomo, Adesuwa, et al.
Publicado: (2021)

Risk factors associated with newly diagnosed attention-deficit/hyperactivity disorder in adults: a retrospective case-control study
por: Schein, Jeff, et al.
Publicado: (2023)

Patient and Care Partner Burden in CKD Patients With and Without Anemia: A US-Based Survey
por: Michalopoulos, Steven N., et al.
Publicado: (2022)

Correction: Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: post hoc analysis
Publicado: (2020)

Costs associated with the administration of erythropoiesis-stimulating agents for the treatment of anemia in patients with non-dialysis-dependent chronic kidney disease: a US societal perspective
por: Gauthier-Loiselle, Marjolaine, et al.
Publicado: (2021)

Assessment of costs associated with adverse events in patients with cancer
por: Wong, William, et al.
Publicado: (2018)

Manifestation of connective tissue diseases (CTD) in pediatrics patients with autoimmune hepatitis (AIH)
por: Garay, S, et al.
Publicado: (2011)

Persistence and Dose Escalation During Maintenance Phase and Use of Nonbiologic Medications Among Patients With Ulcerative Colitis Initiated on Ustekinumab in the United States
por: Zhdanava, Maryia, et al.
Publicado: (2023)

The Comparative Toxicogenomics Database (CTD).
por: Mattingly, Carolyn J, et al.
Publicado: (2003)

Emerging Views on the CTD Code
por: Zhang, David W., et al.
Publicado: (2012)

Uncertainty of Monetary Valued Ecosystem Services – Value Transfer Functions for Global Mapping
por: Schmidt, Stefan, et al.
Publicado: (2016)

Nusinersen for Spinal Muscular Atrophy in the United States: Findings From a Retrospective Claims Database Analysis
por: Gauthier-Loiselle, Marjolaine, et al.
Publicado: (2021)

Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs)
por: Spagnolo, Paolo, et al.
Publicado: (2021)

Chemical-genomic dissection of the CTD code
por: Tietjen, Joshua R., et al.
Publicado: (2010)

ETS Exposure and PAH Body Burden in Nonsmoking Italian Adults
por: Campo, Laura, et al.
Publicado: (2018)

Institutionalization risk and costs associated with agitation in Alzheimer's disease
por: Cloutier, Martin, et al.
Publicado: (2019)

Indicators of Suboptimal Treatment and Associated Healthcare Costs Among Patients With Crohn’s Disease Initiated on Biologic or Conventional Agents
por: Pilon, Dominic, et al.
Publicado: (2022)

Updating the CTD Story: From Tail to Epic
por: Bartkowiak, Bartlomiej, et al.
Publicado: (2011)

Comparative Toxicogenomics Database (CTD): update 2021
por: Davis, Allan Peter, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_e8ro7k684hji2ahrnsiggv44dt